Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)

v3.10.0.1
Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands, shares in Millions
 3 Months Ended 9 Months Ended
Jan. 01, 2018
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Mar. 31, 2018
Dec. 31, 2017
Property, Plant and Equipment [Line Items]              
Unrealized gain (loss) on equity method investments       $ 0 $ 628    
Total revenue   $ 45,663 $ 33,375 191,863 90,638    
Decrease in accumulated deficit   (183,914)   (183,914)     $ (400,924)
Operating income (loss)   23,362 16,493 130,578 39,726    
Milestone payment received       4,600      
Third-party in-licensor portion of milestone payment received       3,000      
Revenue recognized from milestone method revenue       1,600      
Gain (loss) from Viking   62,398 (1,019) 124,206 (3,350)    
Assets, fair value   1,020,595   1,020,595     188,764
Investment in Warrants              
Property, Plant and Equipment [Line Items]              
Assets, fair value   24,284   24,284     3,846
Note Receivable - Viking Therapeutics              
Property, Plant and Equipment [Line Items]              
Assets, fair value   0   0     3,877
Level 1              
Property, Plant and Equipment [Line Items]              
Assets, fair value   131,150   131,150     5,742
Level 1 | Investment in Warrants              
Property, Plant and Equipment [Line Items]              
Assets, fair value   24,284   24,284     3,846
Level 1 | Note Receivable - Viking Therapeutics              
Property, Plant and Equipment [Line Items]              
Assets, fair value   0   0     0
Level 3              
Property, Plant and Equipment [Line Items]              
Assets, fair value   0   0     3,877
Level 3 | Investment in Warrants              
Property, Plant and Equipment [Line Items]              
Assets, fair value   0   0     0
Level 3 | Note Receivable - Viking Therapeutics              
Property, Plant and Equipment [Line Items]              
Assets, fair value   $ 0   $ 0     3,877
Viking Therapeutics, Inc.              
Property, Plant and Equipment [Line Items]              
Equity method investment, ownership (percent)           12.40%  
Outstanding warrants to purchase shares of Viking's common stock (shares)   1.5   1.5      
Warrant exercise price (USD per share)   $ 1.50   $ 1.50      
Recurring | Level 1 | Investment in Warrants              
Property, Plant and Equipment [Line Items]              
Assets, fair value   $ 24,300   $ 24,300     $ 3,800
Accounting Standards Update 2014-09 | Difference between Revenue Guidance in Effect before and after Topic 606              
Property, Plant and Equipment [Line Items]              
Decrease in accumulated deficit $ 25,400            
Operating income (loss) (11,900)            
Accumulated Other Comprehensive Income | Accounting Standards Update 2016-01              
Property, Plant and Equipment [Line Items]              
Unrealized gain (loss) on equity method investments 2,600            
Retained Earnings | Accounting Standards Update 2016-01              
Property, Plant and Equipment [Line Items]              
Unrealized gain (loss) on equity method investments $ 2,600            
Royalty Agreements | Aziyo              
Property, Plant and Equipment [Line Items]              
Effective interest rate for forecasted cash flows (as a percent)       26.00%      
Royalty [Member]              
Property, Plant and Equipment [Line Items]              
Total revenue   36,127 21,931 $ 88,343 60,372    
Royalty [Member] | Calculated under Revenue Guidance in Effect before Topic 606              
Property, Plant and Equipment [Line Items]              
Total revenue   31,600 21,900   60,400    
Promacta              
Property, Plant and Equipment [Line Items]              
Total revenue   27,800   68,200      
Promacta | Calculated under Revenue Guidance in Effect before Topic 606              
Property, Plant and Equipment [Line Items]              
Total revenue   24,800 15,600   41,900    
Kyprolis              
Property, Plant and Equipment [Line Items]              
Total revenue   6,300   14,400      
Kyprolis | Calculated under Revenue Guidance in Effect before Topic 606              
Property, Plant and Equipment [Line Items]              
Total revenue   5,200 4,000   11,600    
Evomela              
Property, Plant and Equipment [Line Items]              
Total revenue   1,300   4,100      
Evomela | Calculated under Revenue Guidance in Effect before Topic 606              
Property, Plant and Equipment [Line Items]              
Total revenue   1,100 1,900   5,100    
Other              
Property, Plant and Equipment [Line Items]              
Total revenue   700   $ 1,600      
Other | Calculated under Revenue Guidance in Effect before Topic 606              
Property, Plant and Equipment [Line Items]              
Total revenue   $ 500 $ 400   $ 1,800